Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cyproterone 5 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cyproterone acetate 5 mg ( DR-2031) | EXPERIMENTAL | 1 tablet daily |
| Cyproterone acetate 15 mg ( DR-2031) | EXPERIMENTAL | 1 tablet daily |
| Cyproterone acetate 25 mg ( DR-2031) | EXPERIMENTAL | 1 tablet daily |
| Placebo | PLACEBO_COMPARATOR | 1 tablet daily |
| Name | Type | Description |
|---|---|---|
| Cyproterone acetate 5 | DRUG | Cyproterone acetate 5 mg |
| Placebo | DRUG | Matching placebo |
| Cyproterone acetate 15 | DRUG | Cyproterone acetate 15 mg |
| Cyproterone acetate 25 | DRUG | Cyproterone acetate 25 mg |
Inclusion Criteria: * Prostate cancer patients who have undergone chemical or surgical castration * History of hot flashes for at least 30 days * Stable prostate cancer therapy for at least 45 days Exclusion Criteria: * Uncontrolled diabetes or severe COPD * History of thromboembolic disease * Li...
Top 20 of 53 competitors
Cyproterone 5 is an investigational small molecule being studied for the treatment of prostate cancer. It is currently in Phase 2 clinical development. The drug is being evaluated for its potential to manage symptoms associated with prostate cancer, specifically hot flashes, in patients undergoing treatment.
Cyproterone 5 is being developed by Teva Pharmaceutical Industries Limited, a company traded on the New York Stock Exchange under the ticker symbol TEVA. The drug is currently in Phase 2 clinical development for the treatment of prostate cancer.
Cyproterone 5 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of prostate cancer, with one completed Phase 2 clinical trial.
Cyproterone 5 has been studied in one clinical trial, identified as NCT00196339. This was a Phase 2, randomized, double-blind, placebo-controlled trial that evaluated the drug for the treatment of hot flashes in prostate cancer patients. The trial was completed and enrolled 315 participants in the United States and Canada.
Yes, Cyproterone 5 is also known as DR-2031. The clinical trial NCT00196339, which studied the drug for hot flashes in prostate cancer patients, refers to the investigational agent as DR-2031. Both names refer to the same drug candidate.